Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir

Overview

Journal Intern Med

Specialty General Medicine

Date 2021 Feb 1

PMID 33518580

Authors

Mai Totsuka

Masayuki Honda

Tatsuo Kanda

Tomotaka Ishii

Naoki Matsumoto

Yoichiro Yamana

Tomohiro Kaneko

Taku Mizutani

Hiroshi Takahashi

Mariko Kumagawa

Reina Sasaki

Ryota Masuzaki

Shini Kanezawa

Kazushige Nirei

Hiroaki Yamagami

Shunichi Matsuoka

Hiroshi Ohnishi

Hiroaki Okamoto

Mitsuhiko Moriyama

Affiliations

Soon will be listed here.

Abstract

A 74-year-old man with a history of transfusion at 35 years old in Egypt was referred to our hospital. He was infected with hepatitis C virus (HCV) genotype 4 (GT4), which is a rare HCV GT in Japan, and was also diagnosed with hepatic compensated cirrhosis. We safely treated the patient for 12 weeks with the combination of glecaprevir and pibrentasvir, and a sustained virologic response (SVR) was achieved. This is the first report of HCV GT4 infection in a treatment-naïve Japanese patient with cirrhosis in whom SVR was achieved with the combination treatment of glecaprevir and pibrentasvir.

References

Hayashi K, Fukuda Y, Nakano I, Katano Y, Toyoda H, Yokozaki S . Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatol Res. 2003; 25(4):409-414. DOI: 10.1016/s1386-6346(03)00016-0. View

Jonas M, Squires R, Rhee S, Lin C, Bessho K, Feiterna-Sperling C . Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study. Hepatology. 2019; 71(2):456-462. PMC: 7028097. DOI: 10.1002/hep.30840. View

Foster G, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R . Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019; 14(1):e0208506. PMC: 6314565. DOI: 10.1371/journal.pone.0208506. View

Sano T, Akuta N, Suzuki F, Kasuya K, Fujiyama S, Kawamura Y . Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis. Intern Med. 2019; 58(18):2657-2662. PMC: 6794189. DOI: 10.2169/internalmedicine.2604-18. View

DAmbrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S . Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2018; 70(3):379-387. DOI: 10.1016/j.jhep.2018.11.011. View

Zuckerman E, Gutierrez J, Dylla D, de Ledinghen V, Muir A, Gschwantler M . Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2020; 18(11):2544-2553.e6. DOI: 10.1016/j.cgh.2020.06.044. View

Brown Jr R, Buti M, Rodrigues L, Chulanov V, Chuang W, Aguilar H . Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. 2019; 72(3):441-449. DOI: 10.1016/j.jhep.2019.10.020. View

Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S . Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42(4):962-73. DOI: 10.1002/hep.20819. View

Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L . Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int. 2015; 9(4):486-507. DOI: 10.1007/s12072-015-9630-4. View

10.

Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad Y . Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2017; 163(1):51-56. DOI: 10.1007/s00705-017-3573-0. View

11.

Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T . Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2017; 53(4):557-565. PMC: 5866824. DOI: 10.1007/s00535-017-1391-5. View

12.

Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng T, Reisch T . Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother. 2018; 62(10). PMC: 6153825. DOI: 10.1128/AAC.01249-18. View

13.

Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto M, Chessa L . Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis. 2020; 53(5):612-619. DOI: 10.1016/j.dld.2020.08.007. View

14.

Reddy K, Pol S, Thuluvath P, Kumada H, Toyota J, Chayama K . Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int. 2017; 38(5):821-833. PMC: 5947593. DOI: 10.1111/liv.13596. View

15.

Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F . Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014; 21(11):762-8. DOI: 10.1111/jvh.12312. View

16.

Kanda T, Matsuoka S, Moriyama M . Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt. Hepatol Int. 2018; 12(4):291-293. DOI: 10.1007/s12072-018-9883-9. View

17.

Guerra J, Garenne M, Mohamed M, Fontanet A . HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012; 19(8):560-7. DOI: 10.1111/j.1365-2893.2011.01576.x. View

18.

Shiha G, Soliman R, ElBasiony M, Hassan A, Mikhail N . Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatol Int. 2018; 12(4):339-347. DOI: 10.1007/s12072-018-9861-2. View

19.

Merli M, Rossotti R, Travi G, Ferla F, Lauterio A, Angelini Zucchetti T . Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV. Transpl Infect Dis. 2019; 21(6):e13165. DOI: 10.1111/tid.13165. View

20.

Borgia S, Hedskog C, Parhy B, Hyland R, Stamm L, Brainard D . Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis. 2018; 218(11):1722-1729. DOI: 10.1093/infdis/jiy401. View